Share buyback program – Ipsen reporting from 13 june to 17 June 2022 – Detailed
Share buyback program – Ipsen reporting from 13 june to 17 June 2022 – Detailed
This article or press release has no online content. Please download the associated documents for more information.
Attachment
![](https://ml-eu.globenewswire.com/media/YWNkNjlhZDctYmZmYi00NDhhLWI4YjYtZThjNzg2MmExMWM0LTEwMTA5NDM=/tiny/Ipsen-SA.png)
Share buyback program – Ipsen reporting from 13 june to 17 June 2022 – Detailed
- 21 June 2022 - 1 mins read
This article or press release has no online content. Please download the associated documents for more information.
Attachment
![](https://ml-eu.globenewswire.com/media/YWNkNjlhZDctYmZmYi00NDhhLWI4YjYtZThjNzg2MmExMWM0LTEwMTA5NDM=/tiny/Ipsen-SA.png)
Related Press Releases
![Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
11 July 2024
6 mins read
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
![IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024 IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
09 July 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024
![Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
09 July 2024
1 mins read
Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
![Half-year statement of IPSEN liquidity agreement – 2024 06 30 Half-year statement of IPSEN liquidity agreement – 2024 06 30](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
08 July 2024
1 mins read
Half-year statement of IPSEN liquidity agreement – 2024 06 30
![IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024 IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
02 July 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024
![Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
02 July 2024
9 mins read
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
![IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024 IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
25 June 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024
![IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024 IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
18 June 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024
![IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024 IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
11 June 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
![Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
10 June 2024
12 mins read